The clinical trial PREFERE aims to recruit 7600 patients with "early intermediate" prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The goal is to confirm noninferiority of cancer-specific survival after external-beam radiotherapy, permanent seed implantation, or active surveillance compared with radical prostatectomy.
Wiegel T, Stöckle M, Bartkowiak D. Are you the author?
Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany; Department of Urology, University Hospital Homburg/Saar, Homburg, Germany.
Reference: Eur Urol. 2014 Sep 27. pii: S0302-2838(14)00911-7.